Altitude Crest Partners’s Zymeworks ZYME Stock Holding History

Altitude Crest Partners’s Portfolio ZYME Stock Details ZYME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-145,581	Closed	-$1.53M	–	28
2024 Q1	$1.53M	Buy	+145,581	New	+$1.62M	0.66%	26

Other funds holding ZYME

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Altitude Crest Partners's ZYME Position: Q2 2024 in Review

Altitude Crest Partners sold out of Zymeworks (ZYME) in Q2 2024, closing a stake of 145,581 shares — an estimated $1.53M sold.

Altitude Crest Partners first reported a position in ZYME in Q1 2024 and held it in 1 quarter. The position peaked at $1.53M in Q1 2024. 164 funds tracked by Wall St. Rank hold ZYME as of Q2 2024.

Altitude Crest Partners reported no remaining Zymeworks position as of Q2 2024 after selling out during the quarter.
Altitude Crest Partners sold 145,581 Zymeworks shares in Q2 2024, an estimated $1.53M.
Altitude Crest Partners first reported a position in Zymeworks in Q1 2024 and held it in 1 quarter.
Altitude Crest Partners's Zymeworks position peaked at $1.53M in Q1 2024.
164 funds tracked by Wall St. Rank held Zymeworks as of Q2 2024.

Based on Altitude Crest Partners's 13F filing for Q2 2024.